A Manchester company at the forefront of COVID-19 testing has launched a landmark trial with Madrid’s universities as the city’s major educational centres re-start face-to-face lessons.
Medusa 19, the developer of the Rapid Saliva Protein Test (RSPT), has begun a pilot which was endorsed by Madrid’s vice president,
Related News
Coronavirus: How to get a Covid test
An increase in demand for coronavirus tests has led to local shortages - with some people being directed to test sites hundreds of miles from their homes. The government...
BBC News 2020-10-22Column: Vaccines an Important Part of a Body’s Ability In Fighting Off Disease
Editor’s Note: This is the fifth in a series of articles prepared by Dr. Paul Kuzma to further public understanding of COVID-19. When we become infected with a...
The Pilot
2020-10-20
UK Vaccine Taskforce has selected Oxford Immunotec as the sole supplier of T cell testing for SARS-CoV-2 specific responses in new COVID vaccine trials
OXFORD, United Kingdom and MARLBOROUGH, Mass., October 22nd 2020 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth...
Pharmiweb 2020-10-22What are COVID-19 'rapid tests' and how accurate are they? Answers to common questions.
BROOKE CAIN The (Raleigh) News & Observer As with everything related to the novel coronavirus, what we know about testing for COVID-19 is constantly changing. When we hear...
News & Record
2020-10-21
Community support needed for EHS Student Council blood drive
The Emporia High School Student Council is asking for the community’s help in filling 190 appointments during its fall blood drive supporting the Red Cross next week. The...
Emporia Gazette
2020-10-22
Trial finds convalescent plasma therapy DOESN'T cut the risk of dying from Covid-19 in crushing ...
A scientific trial has poured cold water on the hope that the blood plasma of recovered Covid-19 patients is an effective treatment for the disease. Convalescent plasma had...
The Daily Mail 2020-10-23UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the 'Company'), a global, high-growth...
Public Technologies 2020-10-22